Effect of chronic treatment with new benzylidene-thiazolidine-2,4-dione (LPSF/GQ-06) with potential hypoglycemic on rat Leydig cell steroidogenesis

@article{Couto2012EffectOC,
  title={Effect of chronic treatment with new benzylidene-thiazolidine-2,4-dione (LPSF/GQ-06) with potential hypoglycemic on rat Leydig cell steroidogenesis},
  author={Jana{\'i}na de Albuquerque Couto and Karina Lidianne Alc{\^a}ntara Saraiva and Cleiton Diniz Barros and Daniel Pedro Udrisar and Christina Alves Peixoto and Juliany Silveira Braglia C{\'e}sar Vieira and Maria do Carmo Alves de Lima and Suely Lins Galdino and Ivan da R. Pitta and Maria In{\^e}s Wanderley},
  journal={Medicinal Chemistry Research},
  year={2012},
  volume={22},
  pages={240-246}
}
Thiazolidinediones work by sensitizing the action of insulin by acting as ligands for the PPAR receptor. This study describes the effects of chronic treatment with new benzylidene-thiazolidine-2,4-dione (LPSF/GQ-06) on Leydig cell steroidogenic capacity, and expression of the steroidogenic acute regulatory protein (StAR) and cholesterol side-chain cleavage… CONTINUE READING